We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Specific Tests Identify Biomarkers for Dermatomyositis

By LabMedica International staff writers
Posted on 16 Sep 2013
Print article
Image: Micrograph of Dermatomyositis from a muscle biopsy (Photo courtesy of Nephron).
Image: Micrograph of Dermatomyositis from a muscle biopsy (Photo courtesy of Nephron).
Specific tests have been developed to identify cancer biomarkers in patients with dermatomyositis, a systemic inflammatory disease.

Most patients with dermatomyositis have auto-antibodies circulating in their bodies that cause distinct clinical disease features and are associated with increased risk of malignancy.

Scientists at Stanford University (Redwood City, CA, USA) performed blood analysis on 111 patients from their Dermatology Clinic and 102 patients from the Johns Hopkins University Myositis Center (Baltimore, MD, USA). Both groups were similar in gender and age at diagnosis.

The team used both immunoblotting and immunoprecipitation techniques to detect antibodies against antitranscriptional intermediary factor-1 (TIF-1γ) and nuclear matrix protein (NXP-2) proteins. The results of the tests showed that 17% of subjects in the two cohorts had antibodies against NXP-2 and 38% had antibodies to TIF-1γ. The specific assays, found 83% of dermatomyositis patients with cancer had a reaction to NXP-2 or TIF-1γ. Further analysis indicates that cancer, older age, and male gender were linked to NXP-2 or TIF-1γ antibodies, with anti-NXP-2 specifically associated with cancer in men.

David F. Fiorentino, MD, PhD, the lead author said, “For the physician treating patients with dermatomyositis, identifying those at higher risk for cancer is a top priority. Our team focused on creating specific tests to detect antibodies against two specific proteins and then testing if those antibodies can identify dermatomyositis patients at higher risk of cancer." Prof. Fiorentino added, “Our findings confirm the link between cancer and age in dermatomyositis, with a sharp increase in frequency at roughly 60 years of age. By determining the presence or absence of NXP-2 and TIF-1γ antibodies, we believe that this will aid clinicians in identifying those with the highest cancer risk." The study was published on September 3, 2103, in the journal Arthritis & Rheumatism.

Related Links:

Stanford University
Johns Hopkins University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Thyroxine ELISA
T4 ELISA
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.